Eudralex Volume 4: Reference and Retention Samples (revised, applicable as of 24 September 2026)
Revised Eudralex Volume 4 guidance on reference and retention samples for medicinal products enters into force.
EC Pharmaceutical Strategy · EU-wide
Source
EC Pharmaceutical Strategy
Regulation
Category
Type · Breadth
Date
Eurobarometers
EC Pharmaceutical Strategy · EU-wideEC Pharmaceutical Strategy: Consultations
EC Pharmaceutical Strategy · EU-wideEU pharmaceutical legislation modernisation: political agreement reached
EU reached agreement to update 20-year-old pharmaceutical rules, strengthening competitiveness and innovation while maintaining safety standards.
EC Pharmaceutical Strategy · EU-wideDG SANTE and EMA sign Working Arrangement with New Zealand Ministry of Health
News announcement 7 July 2026 DG SANTE and EMA sign Working Arrangement with New Zealand Ministry of Health 1 min read
EC Pharmaceutical Strategy · EU-wideVideo message of Commissioner Olivér Várhelyi on the occasion of the Clinical Trials Day 2026
News announcement 20 May 2026 Video message of Commissioner Olivér Várhelyi on the occasion of the Clinical Trials Day 2026 1 min read
EC Pharmaceutical Strategy · EU-wideEC Pharmaceutical Strategy: Publications
Factsheet: The European Biotech Act Factsheet - Revolutionising Clinical Trials Factsheet - Key elements of the EU pharmaceutical reform Factsheet – 30 years of medicines in the EU Factsheet - Critical Medicines Act: ...
EC Pharmaceutical Strategy · EU-wideCommission grants conditional authorisation for medicine treating Duchenne muscular dystrophy
European Commission granted conditional marketing authorisation for a medicine to treat Duchenne muscular dystrophy.
EC Pharmaceutical Strategy · EU-wide
Showing 8 of 8 tracked updates
Health-tech only